- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03958032
Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Among gastrointestinal disease, gastric cancer is a malignancy which is diagnosed predominantly in advanced stages, mostly accompanied with malnutrition when diagnosed, has aggressive behavior with poor oncological outcomes. The only option for curative treatment is surgical resection in this malignancy; however, the surgical procedure itself causes high morbidity and mortality rates. Therefore, physicians combine various treatment modalities and risk assessment to decrease complication and mortality rates.
Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. For the diagnosis of sarcopenia, using the presence of both low muscle mass and decreased muscle function (strength or performance) is recommended. Previous studies showed that colorectal or pancreatic cancer accompanied with sarcopenia has adverse effects on not only for short term and also for long term outcomes. The majority of studies regarding gastric cancer was published from Eastern countries owing to their high incidence. There are few studies from western countries which are mostly retrospective and does not meet the diagnostic criteria of sarcopenia. In the western population, there is no high-quality evidence so far regarding the impact of sarcopenia on early outcomes of gastric cancer surgical treatment.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Trabzon, Tyrkia, 61080
- Karadeniz Technical University, Faculty of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients undergoing gastric surgery for gastric cancer
- Histologically proven gastric adenocarcinoma
- Patients over 18 years
- Patients who agreed to participate in the study
Exclusion Criteria:
- patients treated by non-surgical treatment such as endoscopic treatment, palliative chemotherapy)
- patients received palliative surgery without gastric resection (bypass procedures)
- patients required thoracotomy/thoracoscopy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Participants with gastric cancer
All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
|
No intervention is planned for the participants for the treatment of gastric cancer.
Treatment decision will be in line with clinical practice guidelines.
Surgical team will be blind to the participant's sarcopenia status.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative complications
Tidsramme: within 30 days after surgery
|
complications graded by Clavien-Dindo Complication Classification System
|
within 30 days after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Length of hospital stay
Tidsramme: up to 90 days
|
time interval from the date of operation to the date of discharge
|
up to 90 days
|
|
Mortality
Tidsramme: within 30 days after surgery
|
Dying after surgery
|
within 30 days after surgery
|
|
Readmission rate
Tidsramme: within 30 days after surgery
|
readmission to the hospital because of the adverse events after discharge
|
within 30 days after surgery
|
|
Incidence of sarcopenia
Tidsramme: one day before surgery
|
Sarcopenia consensus defined by The European Working Group on Sarcopenia in Older People
|
one day before surgery
|
|
Muscle mass volume
Tidsramme: one day before surgery
|
muscle mass volume of a cross-sectional computerized- tomography image of the L3, corrected for patient height resulting in L3 muscle index.
|
one day before surgery
|
|
Psoas muscle mass volume
Tidsramme: one day before surgery
|
muscle mass volume of Psoas muscle with 3D reconstruction
|
one day before surgery
|
|
Muscle strength
Tidsramme: one day before surgery
|
evaluated by handgrip strength test (with digital dynamometer)
|
one day before surgery
|
|
Physical performance
Tidsramme: one day before surgery
|
evaluated by 4-meter gait speed test
|
one day before surgery
|
|
Major complication
Tidsramme: within 30 days after surgery
|
grade 3 or higher complications graded by Clavien-Dindo Complication Classification System
|
within 30 days after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ali Guner, MD, Karadeniz Technical University Faculty of Medicine
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
- Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, Tanikawa S, Maeda S, Uemura M, Miyake M, Hama N, Miyamoto A, Ikeda M, Nakamori S, Sekimoto M, Fujitani K, Tsujinaka T. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2016 Jul;19(3):986-93. doi: 10.1007/s10120-015-0546-4. Epub 2015 Sep 25.
- Tegels JJ, van Vugt JL, Reisinger KW, Hulsewe KW, Hoofwijk AG, Derikx JP, Stoot JH. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. J Surg Oncol. 2015 Sep;112(4):403-7. doi: 10.1002/jso.24015. Epub 2015 Aug 31.
- Guner A. Recent trends of gastric cancer treatment in Turkey. Transl Gastroenterol Hepatol. 2017 Apr 26;2:31. doi: 10.21037/tgh.2017.04.01. eCollection 2017.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Sykdommer i nervesystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Nevrologiske manifestasjoner
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Ernæringsforstyrrelser
- Kroppsvekt
- Nevromuskulære manifestasjoner
- Patologiske tilstander, anatomiske
- Endringer i kroppsvekt
- Muskelatrofi
- Atrofi
- Avmagring
- Vekttap
- Neoplasmer i magen
- Sarkopeni
- Underernæring
- Kakeksi
Andre studie-ID-numre
- sarcopenia01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .